<DOC>
	<DOCNO>NCT01569958</DOCNO>
	<brief_summary>Amyotrophic Lateral Sclerosis ( ALS ) neurodegenerative disease characterize progressive weakness muscular atrophy due degeneration loss motor neuron , nerve cell , central nervous system ( motor cortex , brainstem spinal chord ) , control voluntary movement . Riluzole , drug approve ALS treatment , modestly slow disease progression . Transcranial direct current stimulation ( tDCS ) noninvasive technique neuromodulation currently study possible therapeutic tool several neurological psychiatric disease find safe well tolerate . Based experimental evidence animal human subject , tDCS expect reduce motor cortex excitability excitotoxicity , neuronal injury induce excessive glutamatergic stimulation , one postulate pathophysiological mechanism ALS . This study investigate transcranial direct current stimulation motor cortex useful delay disease progression well tolerated ALS patient .</brief_summary>
	<brief_title>Transcranial Direct Current Stimulation Novel Therapeutic Approach Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>This double blind , randomize , placebo-controlled clinical trial . Cathodic tDCS ( 1 mA 20 minute ) sequentially apply motor cortex side , five consecutive day every month twelve month . The control group receive sham stimulation reproduce tactile sensation real stimulation effect central nervous system . For stimulation , researcher employ CE-certified medical device act micro-processor-controlled constant current source . All patient take riluzole entire period study . Fifty-four participant recruit three Italian Centers randomize one two arm study . Disease progression quality life evaluate baseline every three month study . At visit adverse event report tolerability assess specific questionnaire .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>diagnosis probable , laboratorysupported probable , definite amyotrophic lateral sclerosis accord El Escorial revise criterion spinal onset age 18 85 year inclusive disease duration ≤ 24 month disease progression past 3 month FVC ≥ 70 % predict score ≥ 2 item `` swallowing '' ALS Functional Rating Scale Revised score ≥ 2 item `` walking '' ALS Functional Rating Scale Revised treatment steady regimen riluzole minimum 1 month study entry , desire continuation able give inform consent write informed consent bulbar onset previous poliomyelitis motor neuron diseases ALS clinical involvement neurological system pregnancy , lactation , unwillingness contraception require possible contraindication tDCS : metal head ( exclude mouth ) ; electromedical device ; seizure ; drug neurological condition lower seizure threshold ; alcoholism ; severe heart diseases severe disease ALS experimental drug within 1 month prior enrollment drug potentially modify response tDCS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>